> ## Content Index > Fetch the complete content index at: https://newsletters.qs.com/llms.txt > Use this file to discover other available public pages before exploring further. # ๐Ÿ’Š Health Futures #38 - URL: https://newsletters.qs.com/health-futures-38/ - Published: 2024-10-07T11:30:35.000Z - Updated: 2024-10-07T11:30:34.000Z - Description: HolonIQ's Health Newsletter covers the latest developments in hardware and devices, pharmaceuticals, and biotechnology and highlights the week's top health deals. - Author: QS - Tags: Health Skills **Happy Monday ๐Ÿ‘‹** This week, ZEISS Medical Technology, a technology enterprise operating in the optics and optoelectronics industries, [launched](https://www.prnewswire.com/news-releases/zeiss-introduces-its-latest-robotic-visualisation-system-for-neuro-surgery-302260520.html?ref=newsletters.qs.com) the KINEVO 900 S, which is designed for neurosurgery. Olympus Corporation [launched](https://www.biospectrumasia.com/news/101/24970/japanese-medtech-firm-olympus-introduces-new-imaging-platform-visera-s.html?ref=newsletters.qs.com) VISERA S, and Olympus plans to launch VISERA S in Europe, parts of Asia, and Oceania. In the pharmaceuticals sector, Acumen Pharmaceuticals extended its [partnership](https://pharmaceuticalmanufacturer.media/pharma-manufacturing-news/new-drug-development-approvals-regulatory-news/acumen-and-lonza-expand-collaboration-alzheimer-drug/?ref=newsletters.qs.com) with Lonza, where Lonza will manufacture its monoclonal antibody. Meanwhile, Bristol Myers Squibb agreed to a research and licensing [deal](https://www.pharmaceutical-technology.com/news/bms-and-prime-ink-potential-3-5bn-deal-to-develop-t-cell-therapies/?cf-view&ref=newsletters.qs.com) with Prime Medicine in the biotech field. Within health deals, Kailera Therapeutics raised [$400M](https://www.finsmes.com/2024/10/kailera-therapeutics-launches-with-400m-in-series-a-financing.html?ref=newsletters.qs.com) in Series A funding round. ## ๐Ÿ’ป Health Hardware and Devices ๐Ÿค– **ZEISS Medical Technology** [**launched**](https://www.prnewswire.com/news-releases/zeiss-introduces-its-latest-robotic-visualisation-system-for-neuro-surgery-302260520.html?ref=newsletters.qs.com) **the KINEVO 900 S, a new Robotic Visualization System.** The KINEVO 900 S is designed for neurosurgery and other surgical disciplines and offers features such as digital visualization, collaborative assistant functions, and connected intelligence. ๐Ÿฅ **Intuitive, a pioneer of robotic-assisted surgery,** [**expanded**](https://bioalps.org/intuitive-expands-in-the-canton-of-vaud/?ref=newsletters.qs.com) **its European headquarters in Switzerland.** This expansion reflects Intuitive's commitment to its growth in Europe and its focus on creating a fulfilling workplace for its employees. ๐Ÿฉป **Olympus Corporation**[ **announced**](https://www.biospectrumasia.com/news/101/24970/japanese-medtech-firm-olympus-introduces-new-imaging-platform-visera-s.html?ref=newsletters.qs.com) **the launch of VISERA S.** VISERA S, an all-in-one imaging platform with stroboscopy designed to improve ENT diagnostic efficiency and patient experience. ## ๐Ÿ’Š Pharmaceuticals ๐Ÿฉน **Acumen Pharmaceuticals extended its** [**partnership**](https://pharmaceuticalmanufacturer.media/pharma-manufacturing-news/new-drug-development-approvals-regulatory-news/acumen-and-lonza-expand-collaboration-alzheimer-drug/?ref=newsletters.qs.com) **with Lonza.** The partnership aimed to enable the potential future commercial launch of its monoclonal antibody. ๐ŸŽ—๏ธ **Roche to** [**acquire**](https://www.biopharmadive.com/news/roche-regor-cdk-breast-cancer-drug-deal/728410/?ref=newsletters.qs.com) **two experimental breast cancer drugs from Regor Therapeutics for $850M.** The drugs are being developed as next-generation CDK inhibitors, where one of its candidates has shown promising results in early-stage trials. ๐Ÿฉบ **Nxera Pharma** [**partners** ](https://www.thepharmaletter.com/nxera-pharma-and-shionogi-partner-on-quviviq?ref=newsletters.qs.com)**with Shionogi to distribute and sell Quviviq in Japan.** Quviviq secured approval for an insomnia drug in Japan, and this partnership will allow Shionogi to handle the distribution and sales of Quviviq solely in the Japanese market. ## ๐Ÿงฌ Biotechnology ๐Ÿ”ฌ **Bristol Myers Squibb** [**agreed** ](https://www.pharmaceutical-technology.com/news/bms-and-prime-ink-potential-3-5bn-deal-to-develop-t-cell-therapies/?cf-view&ref=newsletters.qs.com)**to a research and licensing deal with Prime Medicine.** The deal allows the development of ex vivo T-cell therapies. Prime Medicine will design gene editing reagents based on its PASSIGE technology, and BMS will take these to develop ex vivo T-cell therapies. ๐Ÿฉธ**CSL Behring**[ **received** ](https://www.thepharmaletter.com/spanish-reimbursement-for-csls-hemgenix?ref=newsletters.qs.com)**a positive recommendation from the Spanish Interministerial Commission on the Pricing of Medicines (CIPM).** Hemgenix is a one-time gene therapy approved for adults with severe and moderately severe hemophilia B. ๐Ÿงช **The number of clinical trials of new drugs in Russia has** [**decreased**](https://www.thepharmaletter.com/russia-faces-ne-wave-of-drop-in-clinical-trials-for-new-drugs?ref=newsletters.qs.com) **by 26.4% year-on-year.** This decline is likely due to reduced investment activities in the local pharmaceutical market. ## **๐Ÿ’ฐ** Deals of the Week ๐Ÿงซ **Kailera Therapeutics** raised [$400M](https://www.finsmes.com/2024/10/kailera-therapeutics-launches-with-400m-in-series-a-financing.html?ref=newsletters.qs.com) in a Series A funding round. The company plans to use the funds to grow and develop its business. ๐Ÿ”ฌ **Aktis Oncology**, a clinical-stage biotechnology company, closed a [$175M](https://www.finsmes.com/2024/09/aktis-oncology-raises-175m-in-series-b-funding.html?ref=newsletters.qs.com) Series B financing. The funds will help advance its differentiated radiopharmaceuticals pipeline. ๐Ÿงช **Mirai Bio**, a MA-based bioplatform innovation company, raised [$50M](https://www.finsmes.com/2024/09/mirai-bio-raises-50m-in-initial-funding.html?ref=newsletters.qs.com). The funds will be used to advance its platform for genetic medicine development across a wide range of therapeutic areas and modalities. ๐Ÿ’ป **Nym**, a NYC-based leader in autonomous medical coding, secured [$47M](https://www.finsmes.com/2024/10/nym-receives-47m-in-growth-funding.html?ref=newsletters.qs.com) in growth funding. ๐Ÿฉบ **Air Doctor**, which specializes in travel health, raised [$20M](https://www.finsmes.com/2024/10/air-doctor-raises-20m-in-series-b-funding.html?ref=newsletters.qs.com) in Series B funding. The funds will accelerate its ongoing expansion in Asia, further consolidating its position as a global market player in travel health. --- **Thank you for reading. Have a great week ahead!** Have some feedback or suggestions? Let us know at hello@holoniq.com [ ](https://newsletters.qs.com/psychedelic-mental-health-treatments-south-asia-health-tech-100-2/)